Miriam Kidron - Oramed Pharmaceuticals Chief Scientific Officer, Director
| ORMP Stock | 8.60 0.02 0.23% |
Director
Dr. Miriam Kidron serves as Chief Scientific Officer and Director at Oramed Pharmaceuticals Inc. Dr. Kidron is a pharmacologist and a biochemist with a Ph.D. in biochemistry. From 1990 to 2007, Dr. Kidron was a senior researcher in the Diabetes Unit at Hadassah University Hospital in Jerusalem, Israel. During 2003 and 2004, Dr. Kidron served as a consultant to Emisphere Technologies Inc., a company that specializes in developing broadbased proprietary drug delivery platforms. Dr. Kidron was formerly a visiting professor at the Medical School at the University of Toronto, and is a member of the American, European and Israeli Diabetes Associations. Dr. Kidron is a recipient of the Bern Schlanger Award. since 2006.
| Age | 76 |
| Tenure | 18 years |
| Phone | 844-967-2633 |
| Web | http://www.oramed.com |
Oramed Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (26.77) % which means that it has lost $26.77 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (78.51) %, meaning that it generated substantial loss on money invested by shareholders. Oramed Pharmaceuticals' management efficiency ratios could be used to measure how well Oramed Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Robert Joyal | Ormat Technologies | 70 | |
| Gilad Rabinovich | Mizrahi Tefahot | 56 | |
| Efraim Halevy | Azrieli Group | 82 | |
| Avi Zigelman | Mizrahi Tefahot | 59 | |
| Shaul Kobrinsky | Israel Discount Bank | 65 | |
| Avraham Guzman | Tower Semiconductor | 79 | |
| HajYehia Samer | Bank Leumi Le Israel | 48 | |
| Miriam Haran | ICL Israel Chemicals | 67 | |
| Yoav Nardi | Bank Leumi Le Israel | 72 | |
| Leo Apotheker | Nice | 65 | |
| Avisar Paz | ICL Israel Chemicals | 63 | |
| Aviad Kaufman | ICL Israel Chemicals | 49 | |
| Ilan Biran | Israel Discount Bank | 69 | |
| Yali Sheffi | Israel Discount Bank | 66 | |
| Yitzhak Sharir | Bank Leumi Le Israel | 66 | |
| Stan Koyanagi | Ormat Technologies | 57 | |
| Shalom Hochman | Israel Discount Bank | 70 | |
| Ami Boehm | Ormat Technologies | 43 | |
| Yodfat Buchris | Israel Discount Bank | 45 | |
| Zehava Simon | Nice | 60 | |
| David Granot | Ormat Technologies | 71 | |
Management Performance
| Return On Equity | -78.51 | |||
| Return On Asset | -26.77 |
Oramed Pharmaceuticals Leadership Team
Elected by the shareholders, the Oramed Pharmaceuticals' board of directors comprises two types of representatives: Oramed Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oramed. The board's role is to monitor Oramed Pharmaceuticals' management team and ensure that shareholders' interests are well served. Oramed Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oramed Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ronald Law, Chief Strategy Officer | ||
| Miriam Kidron, Chief Scientific Officer, Director | ||
| Xiaopeng Li, Independent Director | ||
| Leonard Sank, Independent Director | ||
| Nadav Kidron, President CEO, Director | ||
| Mark Hasleton, Vice President - Business Development | ||
| Xiaoming Gao, Director | ||
| Kevin Rakin, Chairman of the Board, Independent Director | ||
| David Slager, Independent Director | ||
| Hilla Eisenberg, CFO, Treasurer, Secretary | ||
| Aviad Friedman, Independent Director | ||
| Joshua Hexter, COO, Vice President - Business Development | ||
| Avi Gabay, CFO, Treasurer, Secretary |
Oramed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Oramed Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -78.51 | |||
| Return On Asset | -26.77 | |||
| Operating Margin | (584.92) % | |||
| Current Valuation | 156.33 M | |||
| Shares Outstanding | 17.38 M | |||
| Price To Book | 866.13 X | |||
| Revenue | 2.64 M | |||
| Gross Profit | 2.54 M | |||
| EBITDA | (15.43 M) | |||
| Net Income | (15 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oramed Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Oramed Stock refer to our How to Trade Oramed Stock guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Complementary Tools for Oramed Stock analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |